View in EDS PDF Full Text

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

Saved in:
Bibliographic Details
Title: Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
Authors: Zwierzina, H.1 Heinz.Zwierzina@uibk.ac.at, Suciu, S.2, Loeffler-Ragg, J.1, Neuwirtova, R.3, Fenaux, P.4, Beksac, M.5, Harousseau, J.6, Nuessler, V.7, Cermak, J.3, Solbu, G.2, Willemze, R.8, de Witte, T.9, Amadori, S.10
Source: Leukemia (08876924). Nov2005, Vol. 19 Issue 11, p1929-1933. 5p. 2 Diagrams, 3 Charts.
Database: Academic Search Ultimate
Description
ISSN:08876924
DOI:10.1038/sj.leu.2403934